Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 8
Submit an article Journal homepage
508
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW)

Andrea C. Loa Radiation Oncology, BC Cancer, Vancouver, Canada;b Surgery, University of British Columbia, Vancouver, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3253-1071
ORCID Icon,
Ajay Majorc The University of Chicago Medical Center, Chicago, IL, USAORCID Iconhttps://orcid.org/0000-0001-7261-1335
ORCID Icon,
Leanne Superd Children’s Cancer Centre, Monash Children's Hospital, Melbourne, Australia;e Children’s Cancer Centre, Royal Children's Hospital, Melbourne, Australia;f Pediatrics, Monash University, Melbourne, Australia
,
Burton Appelg Pediatric Hematology-Oncology, Joseph M. Sanzari Children's Hospital, Hackensack, NJ, USA
,
Ananth Shankarh Child and Young People’s Cancer Services, University College London Hospitals NHS Foundation Trust, London, UK
,
Louis S. Constinei Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA;j Pediatrics, University of Rochester Medical Center, Rochester, NY, USA
,
Lianna J. Marksk Pediatric Hematology, Oncology, and Stem Cell Transplantation, Stanford University School of Medicine, Stanford, CA, USA
,
Kara M. Kellyl Pediatric Hematology/Oncology, Roswell Park Comprehensive Cancer Center, University at Buffalo, Buffalo, NY, USA
,
Monika L. Metzgerm Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USAORCID Iconhttps://orcid.org/0000-0002-7102-4611
ORCID Icon,
Ilia N. Buhtoiarovn Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Childrenʼs, Cleveland, OH, USA
,
Christine Mauz-Körholzo Pediatric Hematology and Oncology, Justus-Liebig-University of Giessen, Gießen, Germany;p Medical Faculty of the Martin-Luther University of Halle-Wittenberg, Halle, Germany
,
Ana Rosa S. Costaq HematoOnco Pediatra, Hospital de Câncer Infantojuvenil de Barretos, Barretos, Brazil
,
Michael S. Binkleyr Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USAORCID Iconhttps://orcid.org/0000-0002-2640-5255
ORCID Icon &
Jamie Flerlagem Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USAORCID Iconhttps://orcid.org/0000-0002-4182-9355
ORCID Icon show all
Pages 1997-2000 | Received 01 Feb 2022, Accepted 08 Mar 2022, Published online: 31 Mar 2022

References

  • Binkley MS, Rauf MS, Milgrom SA, et al. Stage I–II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood. 2020;135(26):2365–2374.
  • Eichenauer DA, Engert A. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2020;136(26):2987–2993.
  • Regula DP, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med. 1988;318(4):214–219.
  • Xing KH, Connors JM, Al-Mansour M, et al. The outcome of advanced stage nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) compared to classical Hodgkin’s lymphoma (CHL): a matched pair analysis. Blood. 2012;120(21):1531.
  • Appel BE, Chen L, Buxton AB, et al. Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2016;34(20):2372–2379.
  • Borchmann S, Joffe E, Moskowitz CH, et al. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019;133(20):2121–2129.
  • Alonso C, Dutta SW, Mitra N, et al. Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival. Cancer Med. 2018;7(4):1118–1126.
  • Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Hematology Am Soc Hematol Educ Program. 2017;2017(1):324–328.
  • Núñez-García B, Rodríguez-Pertierra M, Sequero S, et al. Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: a report from the Spanish Lymphoma Oncology Group. Hematol Oncol. 2021;39(4):506–512.
  • Shankar AG, Kirkwood AA, Hall GW, et al. Childhood and adolescent nodular lymphocyte predominant Hodgkin lymphoma – a review of clinical outcome based on the histological variants. Br J Haematol. 2015;171(2):254–262.
  • Shankar AG, Roques G, Kirkwood AA, et al. Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome – a report from the SFCE & CCLG groups. Br J Haematol. 2017;177(1):106–115.
  • Shankar A, Daw S. Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents—a comprehensive review of biology, clinical course and treatment options. Br J Haematol. 2012;159(3):288–298.
  • Spinner MA, Varma G, Advani RH. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2019;184(1):17–29.
  • Prasad M, Narula G, Chinnaswamy G, et al. Unfavorable presentation but comparable outcome: presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India. Pediatr Blood Cancer. 2018;65(10):e27288.
  • Verduzco-Aguirre HC, Lopes G, Soto-Perez-De-Celis E. Implementation of diagnostic resources for cancer in developing countries: a focus on PET/CT. Ecancermedicalscience. 2019;13:ed87.
  • Howard SC, Davidson A, Luna-Fineman S, et al. A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: the Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). Pediatr Blood Cancer. 2017;64:e26879.
  • Eichenauer DA, Plütschow A, Fuchs M, et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol. 2015;33(26):2857–2862.
  • Pugliese N, Picardi M, Della Pepa R, et al. Rituximab-containing risk-adapted treatment strategy in nodular lymphocyte predominant Hodgkin lymphoma: 7-years follow-up. Cancers. 2021;13(8):1760.
  • Eichenauer DA, Plütschow A, Fuchs M, et al. Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. Leukemia. 2020;34(3):953–956.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.